Breast Neoplasm Female Clinical Trial
Official title:
Efficacy of Preparation in Self-Hypnosis by Anchoring Versus Conversational Hypnosis, Used Alone or Combined, in Patients Undergoing Breast Macrobiopsies: a Randomized Study
NCT number | NCT05027321 |
Other study ID # | HYACOM |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | October 11, 2022 |
Est. completion date | July 2024 |
The incidence of breast cancer and its mortality are reduced thanks in particular to early detection. Often performed after a screening test, stereotactic macrobiopsies are used to characterize abnormalities detected on mammography. This anxiety-inducing and painful examination leads to significant physiological and psychological modifications for these women who logically apprehend the realization of this act. Faced with this observation, investigators wondered what could be done to improve the experience of the patients during this examination. Investigators were interested in hypnosis because its effectiveness as a complementary practice has been validated by numerous studies with benefits on pain and stress management. However, today, there are no convincing results confirming which hypnosis method would be the best to manage patients' anxiety and pain during this examination.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | July 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - aged 18 or over, - referred to the medical imaging department of Saint-Joseph hospital for breast macrobiopsy, - naive of any hypnosis, - having given free, informed and written consent, - being affiliated to a social security scheme or beneficiary of such scheme Exclusion Criteria: - having a major hearing loss, - suffering from identified mental or psychotic disorders, - not understanding the French language, - having already had hypnosis practices, - having an ongoing pregnancy, - being the subject of a safeguard measure |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Saint Joseph | Marseille |
Lead Sponsor | Collaborator |
---|---|
Hospital St. Joseph, Marseille, France |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in anxiety score | Score (from 20 to 80) measured on the State-Trait Anxiety Inventory for state anxiety (STAI-Y1), how respondent feels right now, at this moment.
Total scores can be categorized into five levels: > 65 (very high), from 56 to 65 (high), from 46 to 55 (medium), from 36 to 45 (low), < 35 (very low). Higher scores mean a worse outcome. |
baseline (pre-intervention, during the intervention, immediatly after the intervetion) and at 8 days | |
Secondary | change in anxiety score | measured on anxiety visual analog scale from 0 (not at all anxious) to 8 (extremely anxious) | baseline (pre-intervention, during the intervention, immediatly after the intervetion) and at 8 days | |
Secondary | change in pain score | measured on pain visual analog scale from 0 (no pain) to 10 (worst pain) | baseline (pre-intervention, during the intervention, immediatly after the intervetion) and at 8 days | |
Secondary | patient examination experience | measured on satisfaction visual analog scale from 0 (poor experience quality) to 10 (very good experience quality) | baseline (immediately after the intervention) | |
Secondary | staff examination experience | measured on satisfaction visual analog scale from 0 (poor experience quality) to 10 (very good experience quality) | baseline (immediately after the intervention) | |
Secondary | anxiety score | STAI-Y2 (score from 20 to 80 measured on the STAI for trait anxiety), how respondent generally feel
Total scores can be categorized into five levels: > 65 (very high), from 56 to 65 (high), from 46 to 55 (medium), from 36 to 45 (low), < 35 (very low). Higher scores mean a worse outcome. |
baseline (pre-intervention) | |
Secondary | Amount of nesthetic administered to the patiet during the procedure | mL | baseline (immediately after the intervention) | |
Secondary | Examination duration | minutes | baseline (immediately after the intervention) | |
Secondary | AE/SAE reporting | baseline (during the intervention, immediatly after the intervetion) and at 8 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03980626 -
Study on Physical Activity's Relationship With Cancer and Cognition
|
N/A | |
Completed |
NCT04329819 -
Satisfaction and QUality of Life After Breast REconstruction
|
||
Recruiting |
NCT03323346 -
Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03900884 -
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer
|
Phase 1 | |
Completed |
NCT05042999 -
The Use of Virtual Reality During Breast Ultrasound-Guided Biopsy Procedures
|
N/A | |
Not yet recruiting |
NCT03662633 -
Diagnosis Value of SEMA4C in Breast Cancer
|
||
Recruiting |
NCT05075512 -
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
Not yet recruiting |
NCT03629509 -
BEFORE Decision Aid Implementation Study
|
N/A | |
Completed |
NCT04811378 -
HaemoCerTM Application in Breast Cancer Surgery
|
N/A | |
Completed |
NCT03198442 -
Breast PET Feasibility
|
N/A | |
Not yet recruiting |
NCT05577442 -
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT04047823 -
Temperature and Injury in Radiotherapy Radiation Skin Injury
|
||
Recruiting |
NCT05452213 -
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
|
Phase 4 | |
Active, not recruiting |
NCT04812652 -
Digitally Distributed Yoga for Women Treated for Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03425838 -
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
|
Phase 3 | |
Completed |
NCT05473026 -
Grateful Strides Toward Physical Activity and Well-Being for Black Breast Cancer Survivors
|
N/A | |
Completed |
NCT04509063 -
Investigating Public Enthusiasm for Mammography Screening in Denmark
|
N/A | |
Recruiting |
NCT05711030 -
Thoracic Paravertebral Block Anesthesia for Breast Cancer Surgery
|
N/A | |
Suspended |
NCT03271853 -
Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.
|
N/A |